188 related articles for article (PubMed ID: 10980226)
1. Positive atrial inotropic effect of dofetilide after cardioversion of atrial fibrillation or flutter.
DeCara JM; Pollak A; Dubrey S; Falk RH
Am J Cardiol; 2000 Sep; 86(6):685-8, A8. PubMed ID: 10980226
[TBL] [Abstract][Full Text] [Related]
2. Acute conversion of atrial fibrillation and flutter: direct current cardioversion versus intravenously administered pure class III agents.
Singh BN
J Am Coll Cardiol; 1997 Feb; 29(2):391-3. PubMed ID: 9014994
[No Abstract] [Full Text] [Related]
3. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
McClellan KJ; Markham A
Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
Bianconi L; Castro A; Dinelli M; Alboni P; Pappalardo A; Richiardi E; Santini M
Eur Heart J; 2000 Aug; 21(15):1265-73. PubMed ID: 10924317
[TBL] [Abstract][Full Text] [Related]
5. Left atrial appendage "stunning" after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events.
Grimm RA; Stewart WJ; Arheart K; Thomas JD; Klein AL
J Am Coll Cardiol; 1997 Mar; 29(3):582-9. PubMed ID: 9060897
[TBL] [Abstract][Full Text] [Related]
6. Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
Sedgwick ML; Lip G; Rae AP; Cobbe SM
Int J Cardiol; 1995 Apr; 49(2):159-66. PubMed ID: 7628887
[TBL] [Abstract][Full Text] [Related]
7. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
Wolbrette DL; Hussain S; Maraj I; Naccarelli GV
J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):3-10. PubMed ID: 29940780
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
[TBL] [Abstract][Full Text] [Related]
9. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
Falk RH; Pollak A; Singh SN; Friedrich T
J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
[TBL] [Abstract][Full Text] [Related]
11. Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.
Khan IA
Am Heart J; 2002 Jul; 144(1):11-22. PubMed ID: 12094183
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.
Lindeboom JE; Kingma JH; Crijns HJ; Dunselman PH
Am J Cardiol; 2000 Apr; 85(8):1031-3. PubMed ID: 10760352
[No Abstract] [Full Text] [Related]
13. Exaggerated QT prolongation after cardioversion of atrial fibrillation.
Choy AM; Darbar D; Dell'Orto S; Roden DM
J Am Coll Cardiol; 1999 Aug; 34(2):396-401. PubMed ID: 10440151
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter].
Vergara G
Ital Heart J Suppl; 2001 Mar; 2(3):322-3. PubMed ID: 11307794
[No Abstract] [Full Text] [Related]
15. Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials.
Thind M; Crijns HJ; Naccarelli GV; Reiffel JA; Corp Dit Genti V; Wieloch M; Koren A; Kowey PR
J Cardiovasc Electrophysiol; 2020 May; 31(5):1022-1030. PubMed ID: 32083368
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
Frost L; Mortensen PE; Tingleff J; Platou ES; Christiansen EH; Christiansen N
Int J Cardiol; 1997 Jan; 58(2):135-40. PubMed ID: 9049678
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
Banchs JE; Baquero GA; Nickolaus MJ; Wolbrette DL; Kelleman JJ; Samii S; Grando-Ting J; Penny-Peterson E; Davidson WR; Young SK; Naccarelli GV; Gonzalez MD
Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of dofetilide for the prevention of atrial tachyarrhythmias (atrial fibrillation or flutter) after coronary artery bypass grafting.
Serafimovski N; Burke P; Khawaja O; Sekulic M; Machado C
Am J Cardiol; 2008 Jun; 101(11):1574-9. PubMed ID: 18489935
[TBL] [Abstract][Full Text] [Related]
19. Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure.
Torp-Pedersen C; Moller M; Kober L; Camm AJ
Eur Heart J; 2000 Aug; 21(15):1204-6. PubMed ID: 10924306
[No Abstract] [Full Text] [Related]
20. Dofetilide: a new pure class III antiarrhythmic agent.
Falk RH; Decara JM
Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
